These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21595599)

  • 1. The risk of tuberculosis in patients treated with TNF antagonists.
    Salgado E; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2011 May; 7(3):329-40. PubMed ID: 21595599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F; Niccoli L; Goletti D
    J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
    Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
    J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
    Hamdi H; Mariette X; Godot V; Weldingh K; Hamid AM; Prejean MV; Baron G; Lemann M; Puechal X; Breban M; Berenbaum F; Delchier JC; Flipo RM; Dautzenberg B; Salmon D; Humbert M; Emilie D;
    Arthritis Res Ther; 2006; 8(4):R114. PubMed ID: 16859506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol and rheumatoid arthritis. Just another TNF alpha antagonist, no therapeutic advantage.
    Prescrire Int; 2010 Dec; 19(111):279. PubMed ID: 21355379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectious complications of tumor necrosis factor blockade.
    Wallis RS
    Curr Opin Infect Dis; 2009 Aug; 22(4):403-9. PubMed ID: 19491672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
    Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
    Sato S; Nagai H
    Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
    Gómez-Reino JJ; Carmona L; Angel Descalzo M;
    Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
    J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF inhibitors for Crohn's disease: when, which, and for how long.
    Med Lett Drugs Ther; 2013 Dec; 55(1432):102-3. PubMed ID: 24419244
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
    Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L;
    Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
    Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of biologic agents in the treatment of inflammatory bowel disease.
    Shepela C
    Minn Med; 2008 Jun; 91(6):42-5. PubMed ID: 18616021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.
    Ramiro S; van Tubergen AM; Landewé RB
    Expert Rev Clin Immunol; 2010 Sep; 6(5):713-20. PubMed ID: 20828279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
    Theis VS; Rhodes JM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.